RT Journal Article
SR Electronic
T1 Nicotine metabolite ratio as an informed biomarker to optimize acupuncture for smoking cessation: randomised controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.23.24315983
DO 10.1101/2024.10.23.24315983
A1 Chen, Shu-min
A1 Ji, Jia
A1 xin, Chai
A1 Li, Yang
A1 Wuyuan
A1 Chang, Jin
A1 MiaoZhang
A1 Liu, Zhen-yu
A1 Tan, Chao-ren
A1 Yang, Jin-sheng
A1 Liu, Zhao
A1 Wang, Ying-ying
YR 2024
UL http://medrxiv.org/content/early/2024/10/25/2024.10.23.24315983.abstract
AB Objective To evaluate the effectiveness of using nicotine metabolite ratio (NMR) as an informed biomarker to optimize acupuncture for smoking cessation.Methods This was a prospective, two-arm, open-label randomized controlled trial. Participants were recruited and classified as slow or normal metabolizers based on their NMR values, and were randomly assigned to high-frequency or low-frequency acupuncture groups. Acupuncture sessions were held 3 to 5 times per week for 8 weeks. Minimum behavioral support was provided. The primary outcome was the 12-week continuous abstinence rate assessed by urine cotinine levels. Secondary outcomes included point abstinence, treatment adherence, and adverse reactions.Results Between September 2018 and April 2022, 220 participants were included. Among them, 211 (95.9%) were male, and the mean (SD) age was 48.5 (11.6) years. With 0.31 as the NMR cut-off value, 70 (31.8%) were divided as normal metabolizers and 150 (68.2%) as slow metabolizers. The validated 3-month sustained abstinence was 17.3% (19/110) in the high-frequency acupuncture group, which was significantly higher than 8.2% (9/110) in the low-frequency acupuncture group (OR=3.89, 95% CI: 1.36, 8.11). In slow metabolizers, the validated 3-month sustained abstinence rate was 19.0% (15/79) in the high-frequency acupuncture, which was higher than 7.0% (5/71) in low-frequency acupuncture (OR=3.53, 95% CI: 1.03, 6.13). In normal metabolizers, the validated 3-month sustained abstinence rates were 12.9% (4/31) in the high-frequency acupuncture group and 10.3% (4/39) in the low-frequency acupuncture group, with high-frequency acupuncture non-inferior to low-frequency acupuncture (OR=1.11, 95% CI: 0.24, 5.17). Treatment adherence was high in both groups, and adverse reactions were infrequent. No serious adverse events were recorded.Conclusion This pioneering study demonstrated that NMR might be used as a biomarker to optimize acupuncture treatments for smoking cessation, particularly among slow metabolizers. This study provides valuable insights into personalized smoking cessation strategies and highlights the potential of integrating acupuncture with other interventions for improved outcomes.Trial Registration Chinese Clinical Trials Registry (No.ChiCTR1800018196), Registered 4 September 2018, (chictr.org.cn).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR1800018196Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Chinese Clinical Trial Ethics Review Committee (Grant No.ChiECRCT-20180135) and registered in the Chinese Clinical Trials Registry (Reg. No. ChiCTR1800018196).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesResearchers who meet the criteria for access to confidential data can access the data from the corresponding author.